E-Qure
Bioelectrical Signal Therapy Device for Chronic Wounds
Company Overview
Snapshot
Founded in January 1988, E-Qure operates with 1–10 employees. The company has secured one public funding round and holds one patent. In February 2017, E-Qure's Bioelectrical Signal Therapy (BST) Device received marketing approval in Israel for chronic wound care.
Business overview
E-Qure develops the Bioelectrical Signal Therapy (BST) Device, a medical technology designed to treat chronic wounds through electrical stimulation. The device functions by mimicking the body's natural electrical currents to stimulate blood flow, oxygen, and local cell regeneration, thereby accelerating wound healing. E-Qure's technology is targeted at severe wounds such as pressure ulcers, diabetic ulcers, and venous ulcers, serving hospitals, nursing homes, and home-care settings within the Health Tech & Life Sciences sector.
Strategic signal
In February 2017, E-Qure's BST Device received marketing approval in Israel for chronic wound care. This regulatory milestone validated the device's efficacy and safety, signaling its readiness for market entry and potential for broader adoption in the medical community. The approval positioned E-Qure to address a significant need in chronic wound management, indicating a positive trajectory for commercialization and patient impact.
Log in to access full profile ›Company Intelligence Q&A
- What is E-Qure's primary product?
- E-Qure's primary product is the Bioelectrical Signal Therapy (BST) Device, which treats chronic wounds via electrical stimulation by imitating natural electrical currents to induce local cell regeneration.
- When was E-Qure founded?
- E-Qure was founded in January 1988.
- What was a key regulatory milestone for E-Qure?
- In February 2017, E-Qure's BST Device for chronic wound care received marketing approval in Israel.
- What is the status of E-Qure?
- E-Qure is currently non-active, having ceased operations in May 2023.
- What markets does E-Qure's technology target?
- E-Qure's BST Device is targeted toward the treatment of chronic wounds in hospitals, nursing homes, and home-care settings globally.